by Stacey Johnson | Dec 29, 2023
It’s been a busy year in the cell and gene therapy community and the bloggers at Signals have enjoyed putting the spotlight on news (HeLa settlement and UK rejoins Horizon Europe), scientific advances (improving treatment for hematological malignancies and a new...
by Tyler Wenzel | Dec 21, 2023
I can recall the first time that I heard about the idea of gene therapy. It was over 20 years ago, and possibly like many students in school, I was assigned to write an essay on the ethical considerations for allowing or disallowing gene editing on humans. I remember...
by Peace Chukwu | Dec 14, 2023
When Caitlin Brodnick tested positive for the BRCA1 gene mutation, she decided to have a preventative double mastectomy. But she was afraid of losing her breasts and worried about the reconstruction, and top on the list was how real they were going to look....
by Stacey Johnson | Dec 8, 2023
Kudos to the clever team at Venair for coming up with the following post on their LinkedIn page: Although I’m tempted to discuss this from a public relations/marketing lens, instead I’m adding these to the list of great gift ideas for the scientist or science lover in...
by Stacey Johnson | Dec 1, 2023
Do you remember the column “Life, Interrupted” by cancer patient Suleika Jaouad? She was 22 when she was diagnosed with acute myeloid leukemia (AML) and a rare blood disorder called myelodysplastic syndrome. With her hopes to be a war correspondent on hold (dashed?),...
by Tyler Wenzel | Nov 23, 2023
Cell therapies that replenish a healthy cell niche have long been an attractive approach to treat a variety of diseases, such as Parkinson’s disease, which are incurable and characterized by the loss of critical cell functions. The attractiveness of cell therapies is...
by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
by Laine Bodnar | Nov 2, 2023
Working in science, whether in academia or industry, can be a rewarding yet challenging experience. For women pursuing careers in these fields, there are unique considerations and issues to be mindful of. As such, the Women in Science Breakfast at the 2023 Till &...
by Kevin Robb | Oct 24, 2023
It was a strange feeling, completing my PhD defense. After immersing myself for years in a highly specific research area, the months leading up to my defense felt like a storm rolling in: my mind became increasingly clouded with technical details, emerging concepts in...
Comments